Effects of ACE inhibition in normotensive patients with chronic glomerular disease and normal renal function  by Bedogna, Valeria et al.
Kidney International, Vol. 38 (1990), pp. 101—107
CLINICAL INVESTIGATION
Effects of ACE inhibition in normotensive patients with
chronic glomerular disease and normal renal function
VALERIA BEDOGNA, ENRICO VALVO, PATRIZIA CASAGRANDE, PAOLO BRAGGIO,
CRISTINA FONTANAROSA, FRANCESCA DAL SANTO, DANIELE ALBERTI, and
GIUSEPPE MAscHIo
Divisione di Nefrologia, Servizio di Medicina Nucleare, and Laboratorio di Analisi Cliniche, Istituto di Radiologia 1, Istituti Ospitalieri,
Verona, and Dipartimento Medico, Ciba-Geigy, Origgio, Italy
Effects of ACE inhibition in normotensive patients with chronic gb-
merular disease and normal renal function. A double-blind, placebo-
controlled study was carried out to assess the effects of a three-month
treatment with a new ACE inhibitor, Benazepnl (BNZ), on systemic
and renal hemodynamics, and urine protein excretion, in 20 patients
with chronic glomerulonephritis, normal blood pressure (130/83 16/10
mm Hg), and normal renal function (creatinine clearance 106 25
mi/mm). Treatments with placebo or BNZ were assigned randomly. A
wide range of proteinuria lowering effect was observed in overall
population (from I to 84%, average 34%). Following the arbitrary level
of a 30% reduction, two well-matched subgroups (10 patients for each
one) were obtained: "good responders" (average decrease 51%), and
"poor responders" (average decrease 17%). The main distinctive
feature between the two groups was a higher plasma renin activity level
in good than in poor responders. A positive correlation between the fall
in proteinuria and blood pressure was found. Although the decrease in
blood pressure seems to represent the major factor in determining the
reduction in proteinuria, a multiple correlation analysis showed that the
most prominent role (7 1%) was attributable to the combined decrease in
blood pressure and filtration fraction, and then also to the efferent
arteriole dilatation. Our conclusion is that ACE inhibitors are capable of
also reducing proteinuria in patients with renal disease with normal
blood pressure, the effect being more pronounced in those exhibiting
humoral, systemic and renal hemodynamic patterns, indicating a
greater activity of circulating and renal renin angiotensin system.
Primary chronic glomerular diseases are the most important
causes of end-stage renal failure in the majority of Western and
Asian countries [1—3]. In virtually all forms of glomerulonephri-
tis, the magnitude of proteinuria has been shown to represent a
significant risk factor for progressive renal functional deterio-
ration [4, 51. Accordingly, the long-term prognosis can be
improved with various therapeutic schedules when remission or
reduction of proteinuria is obtained [6, 7]. Treatment with
steroids, immunosuppressive agents and/or antiplatelet drugs is
often ineffective in adult patients [8, 9]. This may partly be due
to the fact that factors other than those that initiated the disease
process contribute to the progressive loss of nephron mass.
Convincing experimental and clinical evidence has been re-
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ported that angiotensin converting enzyme inhibitors (ACE!)
may prevent or reduce proteinuna [10—13]. These drugs seem
able effectively to reduce glomerular capillary hypertension and
hence to provide protection against glomerular injury, thus
slowing the rate of progression of renal disease in animal studies
[14, 15]. However, no evidence has been reported to our
knowledge to date showing that similar events occur in humans.
Animal models have shown that ACE! can stabilize glomerular
injury even when, as is often the case in clinical practice,
therapy is not initiated until systemic hypertension and glomer-
ular injury are established [14]. Several reports on the effects of
ACE! in patients with primary glomerular disease have been
published. Unfortunately, the patient population was quite
heterogeneous; both hypertensive and normotensive subjects,
with various degrees of renal failure, were treated [12, 16—19].
Not surprisingly, the antiproteinuric effect of ACE! was not
homogeneous in all patients [18, 20, 21], in some cases the
response being dependent on adequate dietary sodium restric-
tion [19]. In addition, all reported studies have been performed
following prospective (or even retrospective) open design. In
the present investigation we have evaluated in a double-blind,
placebo-controlled study, the effects of treatment with a new
ACE!, Benazepril, on proteinuria and on systemic and renal
hemodynamics. Benazepril, belonging to the second generation
of longer acting agents, was administered to patients with
different glomerular diseases, persistent proteinuna and normal
renal function. Nearly all of them were normotensive.
Although structurally different, Benazepril is pharmacogi-
cally similar to enalapril. In experimental animals the ACE
inhibitory capacity of Benazepnl and its effects on renal func-
tion appear to be essentially identical to those produced by
enalapril, using the same dose [22].
Methods
Studies were performed in twenty patients, 15 male and 5
female, with a mean age of 35 years (range 17 to 63), with
primary chronic glomerulopathies and preserved renal function
(Scr 93 15 smol/liter): 10 with IgA nephropathy, 4 with
mesangial proliferative glomerulonephritis, 3 with membrane-
ous glomerulopathy, 2 with focal glomerulosclerosis, and I with
mesangiocapillary glomerulonephntis. Criteria for inclusion in
the study were: 1) persistent proteinuria, equal to or higher than
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1 g/24 hr, with serum protein not lower than 60 g/liter; 2) a
definite histological diagnosis made by means of light micros-
copy and immunofluorescence performed in renal tissue ob-
tained by biopsy [23]; 3) absence of systemic diseases; 4)
normal renal function (Se,. equal to or lower than 124 mo1/
liter). Seven patients were taking antiplatelet agents, and four
antihypertensive therapy other than ACEI. All of them discon-
tinued any treatment for at least six weeks before the study. At
the moment of the inclusion in the study only two patients, with
supine diastolic blood pressure of 100 and 105 mm Hg, respec-
tively, measured with sphygmomanometer, were hypertensive.
All subjects gave their informed consent. They were encour-
aged to maintain their previous dietary habits, with mild restric-
tion of sodium intake (not exceeding 150 to 160 mEqlday). The
study was designed as a double-blind, within-patient, placebo-
controlled trial, carried out according to a crossover design. It
included four periods: Period 0 (2 weeks), single-blind placebo
wash-out period; Period 1 (3 months), 10 mg o.d. Benazepril or
placebo o.d.; Period 2 (2 weeks), single-blind placebo wash-out
period; Period 3 (3 months), placebo o.d. or 10 mg o.d.
Benazepril. At the end of each period, patients were admitted to
hospital for two days, during which routine chemistry, plasma
renin activity (PRA), urine aldosterone, and systemic and renal
hemodynamics were evaluated. Morning supine (8 a.m.) PRA
and 24-hour urine aldosterone were estimated using RIA meth-
ods [24, 25]. Systemic and renal hemodynamics were evaluated
in the morning 24 hours after the last dosing. Glomerular
filtration rate (GFR) and renal plasma flow (RPF) were mea-
sured as the clearance of '251-iothalamate [26] and '311-hippuran
[27]. Patients remained supine when they were not voiding
urine. Effective RPF was calculated as Cl-PAH/E-PAH, where
E-PAH is the extraction ratio of hippuran (=0.91). Renal blood
flow (RBF) was calculated as RPF/1-hematocrit. The clearance
values were adjusted for a body surface area of 1.73 sqm.
Filtration fraction (FF) was obtained as the ratio of GFR and
RPF. Renal vascular resistance (RVR) was calculated following
the Gomez's formula:
MBP
x 80,000 (dyn/s/cm5/l.73 sqm)
where MBP is the mean blood pressure (mm Hg).
The hemodynamic evaluation was carried out in a quiet
room, in the morning after overnight fasting. The patients
relaxed in supine position for at least 30 minutes. The room
temperature was 18 to 22°C and the humidity was 40 to 60%.
Measurement of changes in electrical bioimpedance during the
cardiac cycle was used to estimate changes in cardiac output
(CO) [28, 29], using a commercially available instrument
(BoMed, NCCOM2; BoMed Medical Manufactoring LTD, Ir-
vine, California, USA). This non-invasive method correlates
well with the dye dilution method [291. Two, low contact
impedance, self adhesive electrodes (Red Dot) were placed
around the neck. A third electrode was placed around the
thorax at the level of the xiphoid process, and a fourth around
the upper abdomen 5 cm from the third electrode. The machine
injected the current and performed on-line analysis of a digitally
converted impedance signal using Sramek's equation [301. A
beat to beat printout of the heart rate (HR), cardiac output (CO)
and stroke volume (SV) could be obtained by using the ma-
chine's RS 232 interface. The mean of 20 measurements (one
every thirty seconds) of CO, HR and SY was recorded. The
systolic, diastolic and mean blood pressure (SBP, DBP, MBP)
were measured, always in the left arm, at one minute intervals
for 10 minutes with an automatic BP recorder (Dinamap 845XT,
Ethicon SpA, Divisione Critikon, Rome, Italy; cuff size 23 to 13
cm x 13 cm) [311. The mean value of the measurements was
recorded; the variation among measurements for a single pa-
tient was 4%. The cardiac index (CI) was calculated by dividing
the CO by the body surface area, the stroke index (SI) the CI by
the HR, and the total peripheral resistance index (TPRI) was
calculated according to the formula:
MBP (mm Hg) x 60
TPRI= x1332
CI (L/min/sqm)
and expressed as dyn/s/cm5/sqm.
During the hemodynamic study plasma volume was measured
with the radioactive serum albumin dilution technique [321.
Following basal evaluation, patients were randomly assigned
to the treatment by either placebo or 10 mg Benazepril. Un-
masked formulations were provided by Ciba-Geigy, Italy. Nei-
ther the investigator nor the patients were aware of the type of
the treatment. The patients were followed up by the same
investigator (VB). They took the tablets every morning before
breakfast. During the six months of treatment (placebo and
drug) they were seen every month, as outpatients, 24 hours
after dosing; protein, electrolytes (Na, K, Ca, P) and urea
nitrogen were measured on the urine collected in the previous
24 hours. BP, pulse rate, and body weight were controlled, and
the side-effects registered.
Statistical comparison between placebo and treatment values
was performed using analysis of variance. Comparison between
groups was carried out using the Student's t-test for paired
observations. Linear regression analysis was used for testing
the two variables relationship. Step-down multiple regression
analysis (independent variables: a) percent changes in mean
blood pressure, b) percent changes in filtration fraction, c)
percent changes in renal vascular resistance and d) absolute
pretreatment plasma renin activity; dependent variable: percent
change in urine protein excretion) was performed after a
"standardization" of all considered variables [331. A P value of
less than 0.05 was considered to be statistically significant.
Results
All patients completed the study protocol. The antiprotein-
uric effect of Benazepril was not homogeneous, the percent
decrease ranging from 1 to 84, with an average of 34. For these
reasons, patients were subdivided into two groups, following
the arbitrary level of 30% reduction in proteinuria. Ten patients
were classified as "good responders" and ten as "poor re-
sponders", with more or less than a 30% decrease, respec-
tively, when compared to post-placebo values. Patients in both
groups were matched with respect to sex, age, glomerulopathy
and pretreatment urine Na excretion. Baseline PRA in good
responders was significantly higher (Table 1).
Systemic hemodynamics
As shown in Table 2 good responders had mean blood
pressure level higher than poor responders; the difference,
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Values are mean SD.
Significant difference from placebo:
0.001; d P < 0.0001
however, was not statistically significant. A slight and signifi-
cant reduction in supine systolic, diastolic and mean blood
pressure was observed in the entire group. Two patients who
were hypertensive at beginning of the study became normoten-
sive after Benazepril. Their supine diastolic values, measured
with sphygmomanometer, fell from 100 to 85 and from 105 to 90
mm Hg, respectively. Although statistical significance was not
reached, it is worth noting that the decline in blood pressure
after treatment was more pronounced in good responders, and
was associated with some reduction in total peripheral resis-
tance index. The mean values for cardiac index (lower in poor
responders), pulse rate and plasma volume were statistically
unaltered. No patient complained of symptoms of hypotension,
and no side effects with the drug were recorded.
Renal hemodynamics
Table 3 shows the renal hemodynamic changes after admin-
istration of Benazepril. There were no significant alterations in
renal plasma and blood flows and in glomerular filtration rate in
the entire population. A significant reduction in mean filtration
fraction was seen in all patients. The pre-therapy renal vascular
resistance significantly fell in the entire group and in good
responders. Treatment with Benazepril resulted in a non-
significant decrease in filtration fraction and an increase in renal
plasma and blood flows in good responders.
Urine protein excretion
The mean basal values of urine protein excretion were 3.95
2.86 g124 hr (range 1.0 to 11.0). Although a nephrotic range
proteinuria (>3.5 g/1.73 sqm/24 h) was present in six patients,
no one had a serum protein concentration of less than 60 glliter.
The changes in proteinuria induced by either placebo or
Benazepril in the overall population and in the two subgroups
are reported in Table 4. In addition, the three values of
proteinuria in each patient during each treatment period (pla-
cebo or Benazepril) were averaged, and the mean was calcu-
Table 1. Some characteristics of the two subgroups: good and poor
responders
Good
responders
Poor
responders P
Number 10 10 NS
Sex M8/F2 M7/F3 NS
Age years 33 12 37 12 NS
Glomerulopathy
IgAN 4 6
MPGN 2 2
MGN 2 1
FGS 1 1
MCGN I -
PRA ng/mi/hr 2.18 1.47 1.35 1.23 0.007
U-Na mmoiI24 hr 169 42 166 42 NS
Table 3. Patient characteristics after 3 months of either placebo or
Benazepril
Group Placebo Benazepril P
RPF mI/min/l.73 sqm All 375 85
Good re 373 87
Poor re 377 83
397 70
402 74
393 65
NS
NS
NS
RBF mi/min/1.73 sqm All 664 146
Good re 651 143
Poor re 677 148
712 133
720 142
704 122
NS
NS
NS
GFR m!/min/1.73 sqm All 102 26
Good re 104 31
Poor re 99 20
96 24
96 30
97 16
NS
NS
NS
FF % All 28 8
Good re 29 10
Poor re 27 5
24 624 525 6
<0.05
NS
NS
RVL dyn/s/cm5 All 12502 4089 10815 3138 <0.01
1.73 sqm
Good re 13241 4543
Poor re 11764 3422
10740 3220
10889 3051
<0.02
NS
Abbreviations are: IgA N, IgA nephropathy; MPGN, mesangial
glomerulonephritis; MGN, membraneous glomerulonephritis; FGS, fo-
cal glomerulosclerosis; MCGN, mesangiocapillary glomerulonephritis;
PRA, plasma renin activity.
Table 2. Patient characteristics after 3 months of placebo and
Benazepnl
Abbreviations are: RPF, renal plasma; RBF, blood flows; GFR,
glomerular filtration rate; FF, filtration fraction; RVR, renal vascular
resistance. Values are mean SD.
Table 4. Urine protein excretion (g/24 hr) after one, two and three
months of each treatment with placebo and Benazepril in the overall
population and subgroups
Group N Placebo Benazepril P
SBP mm Hg 133 13 127 14 <0.05
DBP mm Hg 78 13 73 12 <0.05
MBP mm Hg All
Good re
Poor re
20
10
10
96 13
100 12
92 12
90 12
93 12
91 11
<0.05
NS
NS
CI mI/min/sqm All
Good re
Poorre
3605 762
3852 853
3360 511
3654 853
3940 858
3403 554
NS
NS
NS
PR beats/mm 68 8 66 10 NS
TPRI dyn/s/ All 2249 687 2190 729 NS
cm5/sqm
Good re
Poorre
2252 627
2166 797
2001 538
2142 569
NS
NS
PV mi/kg All
Good re
Poor re
39 5
40 5
38 4
40 541 439 5
NS
NS
NS
Overall
population
Good
responders
Poor
responders
Placebo 1 mo. 3.86 2.64 4.20 3.00 3.51 2.10
2 mo. 3.89 2.66 4.71 2.90 3.08 2.06
3 mo. 3.79 2.85 4.67 3.43 2.90 1.70
average 3 mo. 3.80 2.56 4.44 2.92 3.17 1.95
Benazepril I mo. 2.61 l.90c 2.49 2.10" 2.73 1.70a
2 mo. 2.26 l.53c 1.83 l.51c 2.69 1.37
3 mo. 2.12 1.90c 2.14 219b 2.11 1.58"
average 3 mo. 2.38 1.76" 2.16 l.91c 2.61 157b
Percent decrease 34% 51% 17%
Benazepril vs.
placebo
Abbreviations are: SBP, systolic; DBP, diastolic; MBP, mean blood
pressure; CI, cardiac index; PR, pulse rate; TPRI, total peripheral
resistance index; PV, plasma volume; Good re, good responders; Poor
re, poor responders. Values are mean SD.
P <0.02; bp < 0.Ol;CP <
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Table 5. Mean of three urine protein excretion for each patient
during three months of administration of placebo and Benazepril
Percent
Case no. Placebo Benazepril difference
Good responders (N = 10)
1 1.64 0.98 —40
2 2.70 1.34 —50
3 1.85 1.26 —32
4 9.03 5.41 —40
5 1.00 0.63 —37
6 10.14 6.38 —37
7 3.71 1.40 —62
8 5.61 1.79 —68
9 4.91 0.80 —84
10 3.85 1.57 —59
Mean SD 4.44 2.92 2.16 1.91 —51 16
Poor responders (N = 10)
1 5.39 4.50 —17
2 1.31 1.10 —16
3 6.16 4.97 —19
4 6.26 5.01 —20
5 1.53 1.38 —10
6 2.68 2.65 —1
7 2.32 1.81 —22
8 0.92 0.74 —20
9 1.69 1.28 —24
10 3.40 2.65 —22
Mean (SD) 3.17 1.95 2.61 1.57 —17 7
Group (N = 20)
Mean (SD) 3.80 2.56 2.38 1.76 —34 21
lated (average 3 months in Table 4) for all patients and the
subpopulations (good responders and poor responders). Good
responders had pretreatment proteinuria higher than poor re-
sponders, the difference becoming significant after three
months of placebo (P < 0.05). A highly significant reduction in
urine protein excretion was observed in all patients after one
month, and was still evident in the following months. However,
in no patient did proteinuria disappear. The decrease in pro-
teinuria averaged 51% in good responders and 17% in poor
responders (Table 4). The changes in urine protein excretion in
the individual patients during placebo and Benazepril adminis-
tration are shown in Table 5. Changes in protein excretion were
not correlated to the age of the patients, duration of nephrop-
athy, baseline plasma renin activity, changes in renal plasma
and blood flows, glomerular filtration rate, filtration fraction, or
renal vascular resistance, urine sodium excretion. A positive
relationship (r = 0.600, P < 0.005) was noticed between the
individual percent decrements in urine protein excretion and in
mean blood pressure. In the multiple regression analysis model,
two features were found to be jointly explanatory of changes in
proteinuria: differences in mean blood pressure (F 23.29), P <
0.0001) and in filtration fraction (F 19.77, P < 0.0001). Their
values seem to account for 71.45% of the decrease in protein-
uria during Benazepril treatment (Table 6).
Plasma renin activity, urine aldosterone, and laboratory
chemistry
Changes in plasma renin activity, urine aldosterone excretion
and the principal laboratory tests are listed in Table 7. An
expected increase in plasma renin activity and a fall in urine
aldosterone were determined by Benazepril. No changes were
Table 6. Multiple regression analysis (Step-down procedure)
Step Variables F P
% of explained
variability
I RVR
MBP
PRA
FF
0.078
11.490
2.057
19.316
0.868
0.004
0.169
0.001
.
2 MBP
PRA
FF
16. 160
2.150
20.490
0.001
0.159
0.0001
74.83
3 MBP
FF
23.290
19.770
0.0001
0.0001 1.
Dependent variable: percent reduction in urine protein excretion.
Independent variables: RVR, renal vascular resistance; MBP, mean
blood pressure; PRA, plasma renin activity; and FF, filtration fraction.
Table 7. Selected serum and urine values after 3 months of treatment
with placebo and Benazepril
Placebo Benazepril P
PRA ng/ml/hr 1.77 1.45 4.43 2.75 <0.0001
Urinary aldosterone 34.6 13.8 22.1 11.1 <0.05
mo1/24 hr
Serum creatinine j.tmol/liter 94 17 95 18 NS
Creatinine clearance mI/mm 106 25 104 26 NS
Serum Na mmol/liter 143 2 143 1 NS
Serum K mmol/liter 4.40 0.54 4.43 0.50 NS
Serum total protein glliter 67 6 69 5 NS
Serum albumin glliter 41 4 43 4 NS
Urinary urea nitrogen 352 102 377 93 NS
mmol/24 hr
Urinary phosphate mmol/24 hr 21.5 7.4 21.4 7.1 NS
Urinary Na mmol/24 hr 167 42 169 43 NS
Urinary K mmolf24 hr 57 14 56 13 NS
Values are mean SD.
found in the main biochemical parameters after Benazepril in
comparison to placebo treatment.
Discussion
In this study, an effective inhibition of ACE activity during a
three-month treatment with the new ACE inhibitor, Benazepril,
was evidenced by the simultaneous rise in PRA and decrease in
urine aldosterone excretion. The administration of a standard
dose of 10 mg of Benazepril significantly reduced systolië,
diastolic and mean blood pressure in our normotensive patients
with chronic glomerular disease, an effect quite similar to that
reported in other normotensive patients treated with lisinopril
[12, 191. The decline in blood pressure was associated with a fall
in peripheral vascular resistance and no change in cardiac
output and pulse rate, a pattern similar to that obtained with
other ACE inhibitors in hypertensive patients [34, 35]. The
blood pressure-lowering effect appeared unrelated to baseline
plasma renin activity. Pretreatment blood pressure, in the
normal range in almost all individuals, was higher, and the
hypotensive response greater, in good responders (patients with
reduction in proteinuria of more than 30%). Relevant is the fact,
also shown by others [19], that no patient complained from
symptoms of low blood pressure. The renal hemodynamic
pattern shown by our patients after Benazepril was character-
ized by a more consistent decrease in renal than in systemic
vascular resistance (— 13% vs. —3%). Once again this vascular
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response was significantly greater in good responders as com-
pared to poor responders. A concomitant rise, although not
significant, in renal plasma and blood flows was found; glomer-
ular filtration rate was almost unchanged, and as a consequence
an average 14% fall in filtration fraction was recorded in the
overall population. This prevalent renal vasodilatation is con-
sistent with a preferential effect of ACE inhibitors on renal
vascular bed [34, 361, which appears more sensitive to angio-
tensin II than systemic vessels [37]. Our findings indicate that
the dilatation induced by Benazepril was exerted mainly on the
postglomerular arteriole. It is well known that angiotensin II
has a predominant constrictive effect on efferent arteriole [38].
The main purpose of this study was to assess the effect of
Benazepril, in comparison to placebo, on proteinuria in a group
of normotensive patients with primary chronic glomerulone-
phritis and normal renal function. Being a double-blind, place-
bo-controlled study, we chose to give all patients a standard
dose of 10 mg of the drug. Therefore, the possibility that the
antiproteinuric effect of this new ACE inhibitor is dose-related,
as has been reported with lisinopril [19], was not assessed. A
three-month period of treatment with Benazepril was associ-
ated with a fall in mean daily urine protein excretion in almost
all subjects (Table 5). The ten patients who had a fall above the
average (good responders) differed from the poor responders
mainly for their higher PRA (2.18 vs. 1.35 nglml/hr, P < 0.007).
Mean blood pressure, filtration fraction, renal vascular resis-
tance, and urine protein excretion were not significantly dif-
ferent in these two subgroups. In good responders, the mean
PRA values were even greater than normal levels in our
laboratory (1.30 ng/ml/hr on normal Na intake). It has been
proven that the circulating hormones of the renin-angiotensin
system do not necessarily reflect the activity of that system in
the various organs [39]. However, we can argue that both
circulating and renal renin angiotensin systems were more
active in good than in poor responders, and the systemic and
renal hemodynamic changes support the possibility of blockade
of both circulating and intrarenally generated angiotensin II. In
fact, after ACE inhibition, good responders, in addition to
having had a more marked fall in urine protein excretion,
exhibited a greater reduction in blood pressure, renal vascular
resistance and filtration fraction. These results indicate that the
intrarenal dilatation after ACE inhibition was more relevant in
good than in poor responders, and that reduction in vascular
tone occurred predominantly in the efferent arteriole, with a
resultant fall in glomerular capillary pressure. A close relation-
ship was found between the fall in urine protein excretion and
the hypotensive response induced by Benazepril. As clearly
shown by many authors in animal models, lowering of blood
pressure is not necessarily associated with a comparable de-
cline in capillary pressure [40]. However, although the fall in
blood pressure seems to represent a major factor in determining
the reduction of proteinuria in our patients, as well as in other
author's [16], we believe that the renal effects of ACE inhibition
may play some additional role in this relationship. The lack of
correlation between changes in proteinuria and renal vascular
resistance or filtration fraction does not exclude the participa-
tion of renal hemodynamic changes. Indeed, most poor re-
sponders exhibited a sizeable fall in urine protein excretion,
despite stability of their blood pressure. In addition, multiple
correlation analysis considering the fall in urine protein excre-
tion on one hand, and pretreatment plasma renin activity,
changes in mean blood pressure, filtration fraction and renal
vascular resistance on the other hand, clearly showed that the
most prominent role (71.5%) in proteinuria lowering effect was
attributable to the combined decrease in blood pressure and
filtration fraction, the latter being usually considered as an
index of postglomerular resistance.
There are several mechanisms by which ACE inhibitors may
lower proteinuria: 1) antihypertensive activity, it is known that
lowering the blood pressure is followed by some fall in urine
protein excretion, regardless of the administered drugs [16]; 2)
hemodynamic effect, reduced angiotensin II production and
hence decreased glomerular hyperpermeability [41]; 3) antiin-
flammatory and antiplatelet activities; 4) direct effect; 5) in-
volvement of the thiol group. These last properties (3, 4 and 5)
are specifically attributed to captopril [42—45]. It is possible that
a combined effect on systemic blood pressure and glomerular
capillary pressure may explain the results obtained in our
patients. The present observation is in keeping with other
findings in normotensive patients either with incipient diabetic
nephropathy [121 or with primary glomerular disease [19]. In
this case it is possible that, as in diabetic rats, increased
intraglomerular pressure is associated to normal systemic blood
pressure. Although it is hazardous to extrapolate findings of
experimental models to the human pathology, an increased
intraglomerular pressure even in normotensive, chronic glomer-
ulonephritis patients with well preserved renal function could
be found with Benazepril treatment. In summary, we obtained
a significant lowering of proteinuria with the administration of a
new ACE inhibitor, Benazepril, to patients with chronic gb-
merulonephritis and with normal blood pressure and renal
function. The drug was well tolerated, and no subject suffered
from hypotension. The antiproteinuric effect was not uniform
and was not strictly dependent on dietary sodium restriction.
These data seem at variance with those reported by Heeg et a!
[19], probably because the observed salt intake in our patients
was not sufficient to blunt the drug's effect. We separated two
groups with different behavior: the "good responders" and the
"poor responders". The first ones exhibited humoral, systemic
and renal hemodynamic patterns indicating a greater activity of
the circulating and renal renin angiotensin systems.
We conclude that, in patients with primary chronic glomeru-
lar disease, in the absence of a positive response to corticoste-
roids and/or cytotoxic drugs, or when an immunosuppressive
treatment is not clearly indicated, an attempt can be made to
reduce proteinuria, which is associated with a poorer prognosis
in such patients. ACE inhibition may offer a better approach
than both dietary (low protein diet) [46] and non-dietary inter-
vention (NSAIDs, antiplatelet agents) [9, 47] in effectively
lowering urine protein excretion in these patients. However,
further studies are needed with ACE inhibitors along these
lines: first, to confirm their long-term antiproteinuric effect;
second, to establish in which categories of primary glomerular
disease is treatment best indicated; and finally, to estimate their
supposed efficacy in arresting or slowing down the progression
of functional deterioration in renal disease.
Reprint requests to Enrico Valvo, M.D., Divisione di Nefrologia,
Istituti Ospitalieri, 37126 Verona, ha/v.
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